Keros Therapeutics

KROS · NASDAQ

$11.40+$0.34 (+3.07%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.06

Latest news

Press releaseOct 20, 8:59 AM ETPRNewswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Press releaseSep 8, 4:01 PM ETGlobe Newswire
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
NewsMay 14, 8:35 AM ET
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate
NewsMar 4, 4:18 PM ET
Keros Therapeutics: Q4 Earnings Insights
Press releaseMar 4, 4:01 PM ETGlobe Newswire
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Press releaseOct 15, 6:30 AM ETGlobe Newswire
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Press releaseAug 21, 8:30 AM ETPRNewswire
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
Press releaseAug 6, 4:15 PM ETGlobe Newswire
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
NewsJun 10, 2:37 PM ETNabaparna Bhattacharya
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Press releaseJun 9, 3:12 PM ETPRNewswire
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Press releaseMay 29, 6:55 AM ETGlobe Newswire
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
Press releaseMay 21, 8:00 AM ETPRNewswire
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Press releaseMay 19, 8:00 AM ETGlobe Newswire
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
Press releaseMay 12, 12:11 PM ETPRNewswire
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Press releaseMay 8, 2:10 PM ETPRNewswire
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
NewsApr 11, 2:35 PM ETAnthony Noto
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
NewsApr 10, 1:51 PM ETVandana Singh
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
NewsApr 10, 12:12 PM ETAvi Kapoor
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
NewsApr 10, 10:05 AM ETAvi Kapoor
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
NewsApr 1, 8:00 AM ET
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
NewsFeb 27, 7:00 AM ET
Analyst Expectations For Keros Therapeutics's Future
Press releaseFeb 11, 4:43 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Press releaseFeb 4, 3:55 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Press releaseJan 28, 12:55 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Press releaseJan 24, 9:00 PM ETGlobe Newswire
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
Press releaseJan 22, 4:00 PM ETBusiness Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
Press releaseJan 21, 6:15 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
NewsJan 17, 2:00 PM ET
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
NewsJan 15, 4:06 PM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsJan 15, 2:07 PM ETAvi Kapoor
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
NewsJan 15, 12:31 PM ETAvi Kapoor
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
Press releaseJan 8, 12:00 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
Press releaseJan 2, 10:00 AM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
Press releaseDec 27, 3:56 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
NewsDec 16, 4:00 PM ET
Where Keros Therapeutics Stands With Analysts
NewsDec 12, 2:20 PM ETAvi Kapoor
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
NewsDec 12, 12:36 PM ETAvi Kapoor
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
NewsDec 12, 10:44 AM ETAvi Kapoor
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
NewsDec 3, 12:37 PM ETVandana Singh
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Press releaseDec 3, 7:00 AM ETBusiness Wire
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate

Keros Therapeutics: Q4 Earnings Insights

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics

Analyst Expectations For Keros Therapeutics's Future

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views

Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

Where Keros Therapeutics Stands With Analysts

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher

Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook

Nasdaq Down 50 Points; US Initial Jobless Claims Rise

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics